Trial · NCT00131469
Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
NCT00131469, Phase 4, Completed, Oregon Health and Science University; results first posted 2019-04-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta. Trials, record NCT00131469. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00131469
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
- NCT number
- NCT00131469
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 79 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Teriparatide (FORTEO), Placebos
- First posted
- 2005-08-18
- Last updated
- 2019-04-24
- Results first posted
- 2019-04-24
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Spine Bone Mineral Density (BMD) | baseline and 18 months | bone density by dual energy xray absorptiometry |
| Secondary | Total Hip BMD | baseline and 18 months | bone density by dual energy xray absorptiometry |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Spine Bone Mineral Density (BMD) | baseline and 18 months | percentage of change in g/cm2 | MEAN | |
| SECONDARY | Total Hip BMD | baseline and 18 months | percentage of change in g/cm2 | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Spine Bone Mineral Density (BMD) | Teriparatide (FORTEO) | 6.1 | Standard Error 1.5 | percentage of change in g/cm2 | |
| Spine Bone Mineral Density (BMD) | Placebo | 2.8 | Standard Error 1.3 | percentage of change in g/cm2 | |
| Total Hip BMD | Teriparatide (FORTEO) | 2.6 | Standard Error 2 | percentage of change in g/cm2 | |
| Total Hip BMD | Placebo | -2.4 | Standard Error 1.8 | percentage of change in g/cm2 |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Teriparatide (FORTEO) | 38 | |
| Overall Study | STARTED | Placebo | 40 | |
| Overall Study | COMPLETED | Teriparatide (FORTEO) | 29 | |
| Overall Study | COMPLETED | Placebo | 27 | |
| Overall Study | NOT COMPLETED | Teriparatide (FORTEO) | 9 | |
| Overall Study | NOT COMPLETED | Placebo | 13 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Teriparatide (FORTEO) | 0 | 38 |
| Total, all-cause mortality | Placebo | 1 | 40 |
| Total, other adverse events | Teriparatide (FORTEO) | 0 | 38 |
| Total, other adverse events | Placebo | 0 | 40 |
| Total, serious adverse events | Teriparatide (FORTEO) | 0 | 38 |
| Total, serious adverse events | Placebo | 0 | 40 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24463451 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1RR024140 | Oregon Clinical and Translational Research Institute | ORWOLL, ERIC S. | OREGON HEALTH & SCIENCE UNIVERSITY | NATIONAL CENTER FOR RESEARCH RESOURCES | 2006 to 2011 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Teriparatide (FORTEO) vs Placebo: deaths from any cause | Trial comparisons |
| Teriparatide (FORTEO) vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00131469
GET https://conductscience.org/api/trials/v1/NCT00131469/registered